FY2023 EPS Estimates for Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Reduced by Analyst

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at HC Wainwright dropped their FY2023 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a research note issued to investors on Thursday, November 16th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of ($0.56) for the year, down from their prior estimate of ($0.49). HC Wainwright currently has a “Buy” rating and a $4.50 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2023 earnings at ($0.18) EPS, Q1 2024 earnings at ($0.18) EPS, Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.52) EPS.

Unicycive Therapeutics Trading Down 2.0 %

Shares of NASDAQ:UNCY opened at $0.50 on Monday. The business has a 50-day moving average price of $0.70 and a 200 day moving average price of $1.04. The company has a market capitalization of $17.47 million, a price-to-earnings ratio of -0.29 and a beta of 2.64. Unicycive Therapeutics has a 12-month low of $0.40 and a 12-month high of $2.87.

Hedge Funds Weigh In On Unicycive Therapeutics

Several institutional investors have recently bought and sold shares of UNCY. Two Sigma Advisers LP acquired a new position in Unicycive Therapeutics in the 1st quarter valued at about $31,000. Balyasny Asset Management L.P. acquired a new position in Unicycive Therapeutics in the 1st quarter valued at about $1,506,000. Geode Capital Management LLC boosted its stake in shares of Unicycive Therapeutics by 267.3% in the 1st quarter. Geode Capital Management LLC now owns 95,898 shares of the company’s stock valued at $201,000 after buying an additional 69,789 shares during the period. State Street Corp purchased a new position in shares of Unicycive Therapeutics in the 1st quarter valued at about $74,000. Finally, Ground Swell Capital LLC purchased a new position in shares of Unicycive Therapeutics in the 2nd quarter valued at about $26,000. 52.50% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.